Alumis and Kaken Join Forces to Bring Next-Gen Immunotherapy to Japan

A new partnership is set to reshape the treatment landscape for immune-mediated diseases in Japan. Alumis Inc. and Kaken Pharmaceutical Co., Ltd. have signed an exclusive licensing agreement for ESK-001, a highly selective TYK2 inhibitor designed to treat dermatological conditions, with the possibility of expanding to rheumatology and gastrointestinal diseases. Under this collaboration, Alumis will receive $40 million in upfront payments, with the potential for $140 million in milestone-based earnings, while Kaken takes the lead on clinical development, regulatory approvals, and commercialization within Japan. With this agreement, both companies are poised to bring innovative oral immunotherapies to patients who need them most.

This collaboration is fueled by promising Phase 2 clinical data demonstrating ESK-001’s effectiveness in treating immune-related disorders. Alumis CEO Martin Babler emphasized that Kaken’s strong presence in dermatology makes them the perfect partner to ensure ESK-001 reaches patients across Japan. Kaken’s President, Hiroyuki Horiuchi, echoed the enthusiasm, expressing confidence in ESK-001’s potential to transform dermatology treatments and, possibly, other autoimmune diseases. By combining Alumis’ cutting-edge research with Kaken’s market expertise, the two companies are taking an important step toward delivering next-generation immunotherapies to a wider audience.